Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07834736

PMCF Study Fortilink-TS Ti

This study is setup to be able to gather information on the safety and performance of the Fortilink-TS Ti cage of Paradigm Spine GmbH, up to one-year after the surgery. The device is intended to be used in intervertebral fusion surgery. Around 50 participants will participate in this study in 2 hospitals.

The Fortilink-TS Ti cage is meant to be placed in the lower back, to treat degenerative disc disease with up to grade I spondylolisthesis. The study will involve data gathering based on routine care. The study will only entail collection of data (medical history prior to the surgery, data from the surgery and data in the follow up after one year). Fortilink-TS Ti cages are not new, but have been on the market since 2020. The clinical study is performed to actively gather data on the use of this product in the intended group of patients, to monitor its safety and performance. The treatment and follow-up provided in this study does not differ from the standard of care; meaning that participants in the study will receive the same treatment and follow the same follow-up visits and assessments as patients undergoing the same procedure outside of the study.

Recruiting

Interested in participating?

Request Info

Key information

About this study

This study is setup to be able to gather information on the safety and performance of the Fortilink-TS Ti cage of Paradigm Spine GmbH, up to one-year after the surgery. The device is intended to be used in intervertebral fusion surgery. Around 50 participants will participate in this study in 2 hospitals.

The Fortilink-TS Ti cage is meant to be placed in the lower back, to treat degenerative disc disease with up to grade I spondylolisthesis. The study will involve data gathering based on routine care. The study will only entail collection of data (medical history prior to the surgery, data from the surgery and data in the follow up after one year). Fortilink-TS Ti cages are not new, but have been on the market since 2020. The clinical study is performed to actively gather data on the use of this product in the intended group of patients, to monitor its safety and performance. The treatment and follow-up provided in this study does not differ from the standard of care; meaning that participants in the study will receive the same treatment and follow the same follow-up visits and assessments as patients undergoing the same procedure outside of the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to give voluntary informed consent
  • Skeletally mature patients
  • At least 6 months of non-operative treatment
  • Degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels between L2 and S1, with DDD being defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies, and/or up to grade 1 spondylolisthesis of the lumbar spine at one or two contiguous levels between L2 and S1

Exclusion criteria

  • Active systematic infection or an active infection at the operative site
  • A demonstrated allergy or sensitivity to any of the implanted materials
  • Severe osteoporosis (confirmed by imaging in the patient's medical history or during screening)
  • Primary or metastatic tumours affecting the spine (confirmed by imaging in the patient's medical history or during screening)
  • Conditions that may place excessive stresses on the bones and the implants, including but not limited to morbid obesity or other degenerative diseases, at the discretion of the investigator
  • Patients whose ability to follow postoperative restrictions, precautions and rehabilitation programs is limited
  • Fractures, severe deformities or a severe instability in the area of surgery (confirmed by imaging in the patient's medical history or during screening)
  • A medical or surgical situation that would preclude the benefit of surgery
  • Pregnancy
  • Patient's denial for operative treatment, post-operative rehabilitation program, follow up appointments and/or participation in the trial
  • Protocol specified surgical technique cannot be followed for the subject
  • Any other reason (in the judgment of the investigator).

Treatment and study plan

Posterior lumbar interbody fusion surgery

Procedure

Fortilink-TS Ti

Primary outcomes

  1. Change in ODI Score at 12 months follow-up

    Time frame: Improvement in ODI score at 12 months over baseline

    Change between baseline and 12 months follow-up

Secondary outcomes

  1. Change in VAS back and leg pain scores

    Time frame: Baseline to 12 months post-surgery

  2. Incidence in complications and adverse events

    Time frame: Up to 12 months post-surgery

  3. Incidence of imaging-confirmed complications

    Time frame: During follow-up through 12 months post-surgery

    Imaging confirmed complications, such as subsidence, implant migration, or implant failure/breakage, identified during routine follow-up

  4. Radiographic fusion status

    Time frame: During follow-up through 12 months post-surgery

    Fusion status based on imaging performed during routine follow-up

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

BAAT Medical Products B.V.

Industry

Collaborators

  • Archer Research
  • Paradigm Spine

Registry information

Official study title

Post-market Clinical Study of the Fortilink-TS Ti

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 22, 2026
Registry last updated
Sep 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.